DALLAS, Feb. 3, 2014 /PRNewswire/ — Craig Schwimmer, MD, MPH, FACS, Founder and CEO of Snoring Center USA, LLC, is pleased to announce the formation of Pillar Palatal, LLC, and it’s acquisition of the Pillar Procedure business from Medtronic, Inc. effective January 17, 2014. The Pillar Procedure is an FDA cleared, minimally invasive treatment for snoring and mild-to-moderate obstructive sleep apnea. Over 45,000 patients worldwide have received the Pillar Procedure. For more information, please visit: www.pillarprocedure.com

The Snoring Center, based in Dallas, TX, and with offices in Dallas, Houston, Austin, Beverly Hills, Newport Beach, and Atlanta, is the nation’s leading provider of the Pillar Procedure. Pillar Palatal, LLC will manufacture and market the Pillar Procedure to Otolaryngologists across the United States.

According to Dr. Schwimmer, “The Pillar Procedure is the cornerstone of minimally invasive, office based treatment of snoring and sleep apnea. Particularly when combined with other targeted treatments, it is an extremely compelling and attractive option for many patients. With the acquisition of the Pillar technology, we now have the opportunity to increase awareness of this treatment option, and to help Otolaryngologists across the country incorporate it into their treatment models.”

About The Snoring Center and Pillar Palatal, LLC
The Snoring Center is the nation’s leading provider of minimally invasive, office based treatment for snoring and sleep apnea. Founded in 2003 in Dallas, the Company now has offices in Atlanta, Austin, Beverly Hills, Houston, and Newport Beach. The company offers a variety of minimally invasive office based solutions for snoring and sleep apnea, including the Pillar Procedure. For more information, please visit: www.SnoringCenter.com.

Pillar Palatal, LLC was formed as a wholly owned subsidiary of The Snoring Center in 2013 in order to acquire the Pillar Procedure business from Medtronic, Inc. Pillar Palatal will manufacture and market the Pillar Procedure to Otolaryngologists throughout the United States.

This press release contains forward-looking statements. The Company wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with litigation, clinical trials, the regulatory approval process, reimbursement policies and commercialization of new technologies.

Contact:
David B. Kaysen
President and CEO
Pillar Palatal, LLC
214 369 2347
dkaysen@pillarpalatal.com

SOURCE Pillar Palatal, LLC